



10/509941 #2  
PCT/GB 2003 / 001442  
Rec'd PCT/PTO 01 OCT 2004  
INVESTOR IN PEOPLE

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ


REC'D 21 MAY 2003  
WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *AWBauer*

Dated 7 May 2003

**BEST AVAILABLE COPY**

Patents Form 1/77 B  
Patents Act 1977  
(Rule 16)  
THE PATENT OFFICE  
- 5 APR 2002  
NEWPORT

The  
Patent  
Office

1/77

### Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference	100690	05APR02 E708817-1 D02934 P01/7700 0.00-0207863.2	
2. Patent application number (The Patent Office will fill in this part)	0207863.2		
3. Full name, address and postcode of the or of each applicant (underline all surnames)	AstraZeneca AB S-151 85 Sodertalje Sweden  7822448003  Sweden		
Patents ADP number (if you know it)			
If the applicant is a corporate body, give the country/state of its incorporation	Sweden		
4. Title of the invention	BENZAMIDE DERIVATIVES		
5. Name of your agent (if you have one)	Lucy Clare Padget		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	AstraZeneca UK Limited Global Intellectual Property Mereside, Alderley Park Macclesfield Cheshire SK10 4TG		
Patents ADP number (if you know it)	7822471001		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))			

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

Continuation sheets of this form

Description 30

Claim(s) 2

Abstract

Drawing(s) 

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)


Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

  
Authorised Signatory

Date

04/04/2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Lynda M Slack - 01625 - 516173

**Warning**

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

**Notes**

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Benzamide Derivatives

This invention relates to benzamide derivatives, or pharmaceutically acceptable salts or *in vivo* hydrolysable esters or amides thereof. These benzamide derivatives possess histone deacetylase (HDAC) inhibitory activity and accordingly have value in the treatment of disease states associated with cancer (Marks *et al.*, *Nature Reviews*, 1, 194-202, (2001)), cystic fibrosis (Li, S. *et al.*, *J. Biol. Chem.*, 274, 7803-7815, (1999)), Huntingtons chorea (Steffan, J. S. *et al.*, *Nature*, 413, 739-743, (2001)) and sickle cell anaemia (Gabbianelli, M. *et al.*, *Blood*, 95, 3555-3561, (2000)), and accordingly are useful in methods of treatment of a warm-blooded animal, such as man. The invention also relates to processes for the manufacture of said benzamide derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments to inhibit HDAC in a warm-blooded animal, such as man.


In the eukaryotic cell, DNA is compacted to prevent transcription factor accessibility. When the cell is activated this compact DNA is made available to DNA-binding proteins, thereby allowing the induction of gene transcription (Beato, M., *J. Med. Chem.*, 74, 711-724 (1996); Wolffe, A. P., *Nature*, 387, 16-17 (1997)). Nuclear DNA associates with histones to form a complex known as chromatin. The core histones, termed H2A, H2B, H3 and H4 surrounded by 146 base pairs of DNA form the fundamental unit of chromatin, the nucleosome. The N-terminal tails of the core histones contain lysines that are sites for post-transcriptional acetylation. Acetylation neutralizes the potential of the side chain to form a positive charge on the lysine side chain, and is thought to impact chromatin structure.

Histone Deacetylases (HDACs) are zinc-containing enzymes which catalyse the removal of acetyl groups from the  $\epsilon$ -amino termini of lysine residues clustered near the amino terminus of nucleosomal histones. HDACs may be divided into two classes, the first (HDAC 1, 2, 3 and 8) represented by yeast Rpd3-like proteins, and the second (HDAC 4, 5, 6, 7, 9 and 10) represented by yeast Hda1-like proteins. The reversible process of acetylation is important in transcriptional regulation and cell-cycle progression. HDAC deregulation has been associated with several cancers and HDAC inhibitors, such as Trichostatin A (a natural product isolated from *Streptomyces hygroscopicus*), have been shown to exhibit significant anti-tumour effects and inhibition of cell-growth (Meinke, P. T., *Current Medicinal Chemistry*, 8, 211-235 (2001)). Yoshida *et al.*, *Exper. Cell Res.*, 177, 122-131 (1988) teaches

that Trichostatin A causes arrest of rat fibroblasts at the G1 and G2 phases of the cell cycle, thereby implicating HDAC in cell cycle regulation. Furthermore, Trichostatin A has been shown to induce terminal differentiation, inhibit cell growth, and prevent the formation of tumours in mice (Finnin *et al.*, *Nature*, 401, 188-193 (1999)).

5 To date only a few inhibitors of HDAC are known in the art. There is thus a need to identify additional HDAC inhibitors.

Accordingly, the present invention provides a compound of the formula (I):



10 wherein:

Ring A is a heterocyclyl;

$R^1$  is halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl,  $C_{1-6}$ alkanoyloxy,  $N$ -( $C_{1-6}$ alkyl)amino,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>amino,   
 15  $C_{1-6}$ alkanoylamino,  $N$ -( $C_{1-6}$ alkyl)carbamoyl,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>carbamoyl,  $C_{1-6}$ alkylS(O)<sub>a</sub> wherein a is 0 to 2,  $C_{1-6}$ alkoxycarbonyl,  $N$ -( $C_{1-6}$ alkyl)sulphamoyl,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>sulphamoyl or a group (B-E-); wherein,

B is selected from  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{3-8}$ cycloalkyl,  $C_{3-8}$ cycloalkyl $C_{1-6}$ alkyl, phenyl, heterocyclyl, phenyl $C_{1-6}$ alkyl or heterocyclyl $C_{1-6}$ alkyl;   
 20 wherein B may be optionally substituted on carbon by one or more D; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from G;

E is -N( $R^a$ )-, -O-, -C(O)O-, -OC(O)-, -C(O)-, -N( $R^a$ )C(O)-, -C(O)N( $R^a$ )-, -S(O)<sub>r</sub>-, -SO<sub>2</sub>N( $R^a$ )-, -N( $R^a$ )SO<sub>2</sub>-; wherein  $R^a$  is hydrogen or  $C_{1-6}$ alkyl optionally substituted by one or   
 25 more D and r is 0-2;

D is independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl,  $C_{1-6}$ alkanoyloxy,  $N$ -( $C_{1-6}$ alkyl)amino,

$N,N$ -( $C_{1-6}$ alkyl) $_2$ amino,  $C_{1-6}$ alkanoylamino,  $N$ -( $C_{1-6}$ alkyl)carbamoyl,  
 $N,N$ -( $C_{1-6}$ alkyl) $_2$ carbamoyl,  $C_{1-6}$ alkylS(O) $_a$  wherein  $a$  is 0 to 2,  $C_{1-6}$ alkoxycarbonyl,  
 $N$ -( $C_{1-6}$ alkyl)sulphamoyl and  $N,N$ -( $C_{1-6}$ alkyl) $_2$ sulphamoyl;

$G$  is selected from  $C_{1-4}$ alkyl,  $C_{1-4}$ alkanoyl,  $C_{1-4}$ alkylsulphonyl,  $C_{1-4}$ alkoxycarbonyl,  
 5 carbamoyl,  $N$ -( $C_{1-4}$ alkyl)carbamoyl,  $N,N$ -( $C_{1-4}$ alkyl) $_2$ carbamoyl, benzyl, benzyloxycarbonyl,  
 benzoyl and phenylsulphonyl;

$m$  is 0, 1, 2, 3 or 4; wherein the values of  $R^1$  may be the same or different;

$R^2$  is halo;

$n$  is 0, 1 or 2; wherein the values of  $R^2$  may be the same or different;

10  $R^3$  is amino or hydroxy;

$R^4$  is halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy,  
 carbamoyl, mercapto, sulphamoyl,  $C_{1-3}$ alkyl,  $C_{2-3}$ alkenyl,  $C_{2-3}$ alkynyl,  $C_{1-3}$ alkoxy,  
 $C_{1-3}$ alkanoyl,  $C_{1-3}$ alkanoyloxy,  $N$ -( $C_{1-3}$ alkyl)amino,  $N,N$ -( $C_{1-3}$ alkyl) $_2$ amino,  
 $C_{1-3}$ alkanoylamino,  $N$ -( $C_{1-3}$ alkyl)carbamoyl,  $N,N$ -( $C_{1-3}$ alkyl) $_2$ carbamoyl,  $C_{1-3}$ alkylS(O) $_a$   
 15 wherein  $a$  is 0 to 2,  $C_{1-3}$ alkoxycarbonyl,  $N$ -( $C_{1-3}$ alkyl)sulphamoyl,  $N,N$ -( $C_{1-3}$ alkyl) $_2$ sulphamoyl;

$p$  is 0, 1 or 2; wherein the values of  $R^4$  may be the same or different;

or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester or amide thereof;

with the proviso that said compound is not  $N$ -(2-amino-6-hydroxyphenyl)-4-(1-  
 methylhomopiperazin-4-yl)lbenzamide;  $N$ -(2-amino-6-methylphenyl)-4-(1-  
 20 methylhomopiperazin-4-yl)lbenzamide;  $N$ -(2-aminophenyl)-4-(1-  
 butoxycarbonylhomopiperazin-4-yl)lbenzamide; or  $N$ -(2-aminophenyl)-4-(1-  
 methylhomopiperazin-4-yl)lbenzamide.

In this specification the term "alkyl" includes both straight and branched chain alkyl  
 groups. For example, " $C_{1-6}$ alkyl" includes methyl, ethyl, propyl, isopropyl and *t*-butyl.  
 25 However, references to individual alkyl groups such as 'propyl' are specific for the straight-  
 chained version only and references to individual branched chain alkyl groups such as  
 'isopropyl' are specific for the branched chain version only. The term "halo" refers to fluoro,  
 chloro, bromo and iodo.

Where optional substituents are chosen from "one or more" groups it is to be  
 30 understood that this definition includes all substituents being chosen from one of the specified  
 groups or the substituents being chosen from two or more of the specified groups.

A "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 3-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a ring sulphur atom may be optionally oxidised to form the S-oxide(s). Preferably a "heterocyclyl" is

5 a saturated, partially saturated or unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen or a 10 membered bicyclic ring which may, unless otherwise specified, be carbon or nitrogen linked, wherein a ring sulphur atom may be optionally oxidised to form S-oxide(s). Examples and suitable values of the term "heterocyclyl" are thiazolidinyl, pyrrolidinyl, 2-pyrrolidonyl, 2,5-dioxopyrrolidinyl,

10 2,4-dioxoimidazolidinyl, 2-oxo-1,3,4-(4-triazolinyl), 2-oxazolidinonyl, 5,6-dihydrouracilyl, 1,3-benzodioxolyl, 1,2,4-oxadiazolyl, 2-azabicyclo[2.2.1]heptyl, 4-thiazolidonyl, morpholino, 2-oxotetrahydrofuranyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, piperidyl, piperazinyl, thiomorpholino, 1,1-dioxothiomorpholino, tetrahydropyranyl, 1,3-dioxolanyl, homopiperazinyl, thienyl, isoxazolyl, imidazolyl, thiadiazolyl, isothiazolyl, 1,2,4-triazolyl,

15 1,3,4-triazolyl, pyranyl, indolyl, pyrimidyl, thiazolyl, pyrazinyl, pyridazinyl, pyridyl, 4-pyridonyl, quinolyl and 1-isoquinolonyl.

An example of "C<sub>1-6</sub>alkanoyloxy" is acetoxy. Examples of "C<sub>1-6</sub>alkoxycarbonyl" and C<sub>1-4</sub>alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl, *n*- and *t*-butoxycarbonyl. Examples of "C<sub>1-6</sub>alkoxy" include methoxy, ethoxy and propoxy. Examples of

20 "C<sub>1-6</sub>alkanoylamino" and C<sub>1-3</sub>alkanoylamino include formamido, acetamido and propionylamino. Examples of "C<sub>1-6</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2" include C<sub>1-4</sub>alkylsulphonyl, C<sub>1-3</sub>alkylS(O)<sub>a</sub>, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of "C<sub>1-6</sub>alkanoyl" and C<sub>1-4</sub>alkanoyl include C<sub>1-3</sub>alkanoyl, propionyl and acetyl. Examples of "N-C<sub>1-6</sub>alkylamino" and N-(C<sub>1-3</sub>alkyl)amino include methylamino and

25 ethylamino. Examples of "N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino" and N,N-(C<sub>1-2</sub>alkyl)<sub>2</sub>amino include di-N-methylamino, di-(N-ethyl)amino and N-ethyl-N-methylamino. Examples of "C<sub>2-6</sub>alkenyl" are C<sub>2-3</sub>alkenyl, vinyl, allyl and 1-propenyl. Examples of "N-(C<sub>1-6</sub>alkyl)sulphamoyl" are N-(C<sub>1-3</sub>alkyl)sulphamoyl, N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl. Examples of "N-(C<sub>1-6</sub>alkyl)<sub>2</sub>sulphamoyl" are N,N-(C<sub>1-3</sub>alkyl)<sub>2</sub>sulphamoyl, N,N-(dimethyl)sulphamoyl and

30 N-(methyl)-N-(ethyl)sulphamoyl. Examples of "N-(C<sub>1-6</sub>alkyl)carbamoyl" are N-(C<sub>1-4</sub>alkyl)carbamoyl, N-(C<sub>1-3</sub>alkyl)carbamoyl, methylaminocarbonyl and ethylaminocarbonyl. Examples of "N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl" are N,N-(C<sub>1-4</sub>alkyl)carbamoyl, N,N-(C<sub>1-2</sub>alkyl)<sub>2</sub>carbamoyl, dimethylaminocarbonyl and methylethylaminocarbonyl. Examples

of "heterocyclylC<sub>1-6</sub>alkyl" include pyridylmethyl, 3-morpholinopropyl, 2-morpholinoethyl and 2-pyrimid-2-ylethyl. Examples of "heterocyclylthio" include thienylthio and pyridylthio.

Examples of "C<sub>3-8</sub>cycloalkyl" include cyclopropyl and cyclohexyl. Examples of

"C<sub>3-8</sub>cycloalkylC<sub>1-6</sub>alkyl" include cyclopropylmethyl and 2-cyclohexylpropyl. Examples of

5 "C<sub>1-6</sub>alkoxycarbonylamino" include methoxycarbonylamino and *t*-butoxycarbonylamino.

A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example acetic, hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid.

10 In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or

15 tris-(2-hydroxyethyl)amine.

The compounds of the formula (I) may be administered in the form of an *in vivo* hydrolysable ester or *in vivo* hydrolysable amide of a compound of the formula (I).

An *in vivo* hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the

20 human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically acceptable esters for carboxy include C<sub>1-6</sub>alkoxymethyl esters for example methoxymethyl, C<sub>1-6</sub>alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C<sub>3-8</sub>cycloalkoxycarbonyloxyC<sub>1-6</sub>alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and

25 C<sub>1-6</sub>alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

An *in vivo* hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and  $\alpha$ -acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the

30 parent hydroxy group. Examples of  $\alpha$ -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of *in vivo* hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl,



alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and *N*-(*N,N*-dialkylaminoethyl)-*N*-alkylcarbamoyl (to give carbamates), *N,N*-dialkylaminoacetyl and carboxyacetyl. Examples of substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring.

5 A suitable value for an *in vivo* hydrolysable amide of a compound of the formula (I) containing a carboxy group is, for example, a *N*-C<sub>1-6</sub>alkyl or *N,N*-di-C<sub>1-6</sub>alkyl amide such as *N*-methyl, *N*-ethyl, *N*-propyl, *N,N*-dimethyl, *N*-ethyl-*N*-methyl or *N,N*-diethyl amide.

Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (*E*- and *Z*- isomers), and it is to be understood that the invention encompasses all such  
10 optical, diastereoisomers and geometric isomers that possess HDAC inhibitory activity.

The invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess HDAC inhibitory activity.

Further values of Ring A, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, m, n and p are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined  
15 hereinbefore or hereinafter.

Ring A is a pyridyl, quinolyl, indolyl, pyrimidyl, morpholinyl, piperidiny, piperazinyl, pyradazinyl, pyrazinyl, thiazyl, oxazolyl, isoxazolyl, isothiazolyl, pyrazolyl, or furanyl.

Ring A is a pyridyl, quinolyl, pyrimidyl, morpholinyl, piperidiny, piperazinyl,  
20 pyradazinyl, pyrazinyl, thiazyl or furanyl.

Ring A is a pyridin-4-yl, pyridin-3-yl, pyridin-2-yl, quinoline-8-yl, pyradizin-2-yl, furan-3-yl, morpholinyl, thiazol-2-yl, pyrimidin-6-yl, piperidin-4-yl or piperazin-4-yl.

Ring A is pyridin-4-yl, pyridin-3-yl, quinoline-8-yl, piperidin-4-yl or piperazin-4-yl.

R<sup>1</sup> is halo, amino, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, C<sub>1-3</sub>alkanoyloxy, *N*-(C<sub>1-3</sub>alkyl)amino,  
25 *N,N*-(C<sub>1-3</sub>alkyl)<sub>2</sub>amino, C<sub>1-3</sub>alkanoylamino, *N*-(C<sub>1-3</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-3</sub>alkyl)<sub>2</sub>carbamoyl.

R<sup>1</sup> is halo, amino, C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkoxy.

R<sup>1</sup> is halo, amino, methyl or methoxy.

m is 0, 1, 2, 3 or 4; wherein the values of R<sup>1</sup> may be the same or different.

30 m is 0, 1, or 2; wherein the values of R<sup>1</sup> may be the same or different.

m is 0 or 1.

m is 0.

m is 1.

R<sup>2</sup> is halo.

R<sup>2</sup> is fluoro or chloro.

R<sup>2</sup> is fluoro.

5 n is 0, 1 or 2, wherein the values of R<sup>2</sup> may be the same or different.

n is 0 or 1.

n is 0.

n is 1.

R<sup>3</sup> is amino or hydroxy.

10 R<sup>3</sup> is amino.

R<sup>3</sup> is hydroxy.

R<sup>4</sup> is halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy or carbamoyl.

R<sup>4</sup> is halo, cyano, trifluoromethyl or trifluoromethoxy.

15 R<sup>4</sup> is halo.

p is 0, 1 or 2, wherein the values of R<sup>4</sup> may be the same or different.

p is 0 or 1.

p is 0.

p is 1.

20 Therefore in an additional aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein:

Ring A is a pyridyl, quinolyl, indolyl, pyrimidyl, morpholinyl, piperidinyl, piperazinyl, pyradazinyl, pyrazinyl, thiazyl, oxazolyl, isoxazolyl, isothiazolyl, pyrazolyl, or furanyl;

25 R<sup>1</sup> is halo, amino, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, C<sub>1-3</sub>alkanoyloxy, *N*-(C<sub>1-3</sub>alkyl)amino, *N,N*-(C<sub>1-3</sub>alkyl)<sub>2</sub>amino, C<sub>1-3</sub>alkanoylamino, *N*-(C<sub>1-3</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-3</sub>alkyl)<sub>2</sub>carbamoyl.

m is 0, 1, 2, 3 or 4; wherein the values of R<sup>1</sup> may be the same or different;

R<sup>2</sup> is fluoro or chloro;

30 n is 0, 1 or 2, wherein the values of R<sup>2</sup> may be the same or different;

R<sup>3</sup> is amino or hydroxy;

R<sup>4</sup> is halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy or carbamoyl;

p is 0, 1 or 2, wherein the values of  $R^4$  may be the same or different;  
or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester or amide thereof.

Therefore in an additional aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein:

5 Ring A is a pyridyl, quinolyl, pyrimidyl, morpholinyl, piperidinyl, piperazinyl, pyradazinyl, pyrazinyl, thiazyl or furanyl;

$R^1$  is halo, amino, methyl or methoxy;

m is 0, 1, or 2; wherein the values of  $R^1$  may be the same or different;

$R^2$  is fluoro;

10 n is 0 or 1;

$R^3$  is amino;

$R^4$  is halo;


p is 0, 1 or 2, wherein the values of  $R^4$  may be the same or different;

or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester or amide thereof.


15 In another aspect of the invention, preferred compounds of the invention are any one of Examples 1-8 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester or amide thereof.

Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof  
20 which process (wherein Ring A,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , m, n and p are, unless otherwise specified, as defined in formula (I)) comprises of:

(a) The reaction of a compound of the formula (II)




25 wherein X is a reactive group, with a compound of the formula (III)




wherein  $L^1$  and  $L^2$  are ligands;

(b) The reaction of a compound of the formula (IV)




wherein  $L^1$  and  $L^2$  are ligands, with a compound of the formula (V)




wherein X is a reactive group;

(c) The reaction, in the presence of 4-(4,6-dimethoxy-1,3,5-triazinyl-2-yl)-4-methylmorpholinium chloride, of a compound of the formula (VI)



with a compound of the formula (VII)



and thereafter if necessary:

i) converting a compound of the formula (I) into another compound of the formula (I);

5 ii) removing any protecting groups;

A suitable base for process (a), (b) or (c) is, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or, for example, an alkali or alkaline earth metal carbonate or hydroxide, for example sodium carbonate,  
 10 potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide, or, for example, an alkali metal hydride, for example sodium hydride, or a metal alkoxide such as sodium ethoxide;

A suitable reactive group X is, for example, a halogeno, alkoxy, aryloxy or sulphonyloxy group, for example a chloro, bromo, methoxy, phenoxy, methanesulphonyloxy,  
 15 trifluoromethanesulphonyloxy or toluene-4-sulphonyloxy group. The reactions are conveniently carried out in the presence of a suitable inert solvent or diluent, for example an alkanol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran, 1,2-dimethoxyethane or 1,4-dioxan, an aromatic solvent such as toluene, or a  
 20 dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide. The reactions are conveniently carried out at a temperature in the range, for example, 10 to 250°C, preferably in the range 40 to 80°C;

A suitable value for the ligands  $L^1$  and  $L^2$  which are present on the boron atom include, for example, a hydroxy, (1-4C)alkoxy or (1-6C)alkyl ligand, for example a hydroxy,  
 25 methoxy, ethoxy, propoxy, isopropoxy, butoxy, methyl, ethyl, propyl, isopropyl or butyl ligand. Alternatively the ligands  $L^1$  and  $L^2$  may be linked such that, together with the boron atom to which they are attached, they form a ring. For example,  $L^1$  and  $L^2$  together may define an oxy-(2-4C)alkylene-oxy group, for example an oxyethyleneoxy or

oxytrimethyleneoxy group such that, together with the boron atom to which they are attached, they form a cyclic boronic acid ester group;

A suitable catalyst for process (a) or (b) includes, for example, a metallic catalyst such as a palladium(0), palladium(II), nickel(0) or nickel(II) catalyst, for example  
5 tetrakis(triphenylphosphine)palladium(0), palladium(II) chloride, palladium(II) bromide, bis(triphenylphosphine)palladium(II) chloride, tetrakis(triphenylphosphine)nickel(0), nickel(II) chloride, nickel(II) bromide or bis(triphenylphosphine)nickel(II) chloride. In addition a free radical initiator may conveniently be added, for example an azo compound such as azo(bisisobutyronitrile);

10 It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent  
15 by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as  
20 aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric  
25 acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard  
30 practice (for illustration see T.W. Green, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

Biological Assays

The following assays can be used to measure the effects of the compounds of the present invention as HDAC inhibitors, as inhibitors *in vitro* of pooled histone deacetylases from nuclear extracts prepared from the human cervical cancer cell line HeLa, and as inducers *in vitro* of Histone H3 acetylation in whole cells

(a) In Vitro Enzyme Assay of Pooled Histone Deacetylases

HDAC inhibitors were screened against pooled histone deacetylases from nuclear extracts prepared from the human cervical cancer cell line HeLa.

The deacetylase assays were carried out in a 40  $\mu$ l reaction. 2.5  $\mu$ g of nuclear extract diluted in 15  $\mu$ l of reaction buffer (25 mM TrisHCl (pH 8), 137 mM NaCl, 2.7 mM KCl, 1 mM  $MgCl_2$ ) was mixed with either buffer alone (5  $\mu$ l) or buffer containing compound (5  $\mu$ l) for 30 minutes at ambient temperature. 25  $\mu$ M fluor-de-lys substrate (Biomol) diluted in 20  $\mu$ l of buffer was then added to the reaction and incubated for one hour at ambient temperature.

The reaction was stopped by addition of an equal volume (40  $\mu$ l) fluor de lys developer (Biomol) containing Trichostatin A at 2  $\mu$ M. The reaction was allowed to develop for 30 minutes at ambient temperature and then fluorescence measured at an excitation wavelength of 360 nM and an emission wavelength of 465 nM. IC<sub>50</sub> values for HDAC enzyme inhibitors were determined by performing dose response curves with individual compounds and determining the concentration of inhibitor producing fifty percent decrease in the maximal signal (no inhibitor control).

(b) In Vitro Enzyme Assay of Histone Deacetylase activity in whole cells

Histone H3 acetylation in whole cells using immunohistochemistry and analysis using the Cellomics arrayscan. A549 cells were seeded in 96 well plates at  $1 \times 10^4$  cells/well, and allowed to adhere overnight. They were treated with inhibitors for 24 hours and then fixed in 1.8% formaldehyde in tris buffered saline (TBS) for one hour. Cells were permeabilized with ice-cold methanol for 5 minutes, rinsed in TBS and then blocked in TBS 3% low-fat dried milk for 90 minutes. Cells were then incubated with polyclonal antibodies specific for the acetylated histone H3 (Upstate #06-599) diluted 1 in 500 in TBS 3% milk for one hour. Cells were rinsed three times in TBS and then incubated with fluorescein conjugated secondary antibodies (Molecular Probes #A11008) & Hoechst 333542 (1  $\mu$ g/ml) (Molecular Probes #H3570) in TBS 1% Bovine serum albumin (Sigma #B6917) for one hour. Unbound antibody



was removed by three rinses with TBS and after the final rinse 100  $\mu$ l of TBS was added to the cells and the plates sealed and analysed using the Cellomics arrayscan.

EC<sub>50</sub> values for HDAC inhibitors were determined by performing dose response curves with individual compounds and then determining the concentration of inhibitor producing fifty percent of the maximal signal (reference compound control - Trichostatin A (Sigma)).

Although the pharmacological properties of the compounds of the formula (I) vary with structural change as expected, in general activity possessed by compounds of the Formula I, may be demonstrated at the following concentrations or doses in one or more of the above tests (a) and (b):-

Test (a):- IC<sub>50</sub> in the range, for example, < 50.0  $\mu$ M;

Test (b):- EC<sub>50</sub> in the range, for example, < 9.0  $\mu$ M;

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester or amide thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.

The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.

In general the above compositions may be prepared in a conventional manner using conventional excipients.

The compound of formula (I) will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg/kg, and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient. Preferably a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.

According to a further aspect of the present invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester or amide thereof, as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.

5 We have found that the compounds defined in the present invention; or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester or amide thereof, are effective cell cycle inhibitors (anti-cell proliferation agents), which property is believed to arise from their HDAC inhibitory properties. We also believe that the compounds of the present invention may be involved in the inhibition of angiogenesis, activation of apoptosis and  
10 differentiation. Accordingly the compounds of the present invention are expected to be useful in the treatment of diseases or medical conditions mediated alone or in part by HDAC enzymes, i.e. the compounds may be used to produce a HDAC inhibitory effect in a warm-blooded animal in need of such treatment. Thus the compounds of the present invention provide a method for treating the proliferation of malignant cells characterised by inhibition of  
15 HDAC enzymes, i.e. the compounds may be used to produce an anti-proliferative effect mediated alone or in part by the inhibition of HDACs.

Thus according to this aspect of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester or amide thereof, as defined hereinbefore for use as a medicament; and the use of a compound of the  
20 formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester or amide thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal such as man.

According to a further feature of this aspect of the invention there is provided a  
25 method for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester or amide thereof, as defined hereinbefore.

According to an additional feature of this aspect of the invention there is provided a  
30 method of treating cancers in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the

formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester or amide thereof, as defined hereinbefore.

According to an additional feature of this aspect of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester or amide thereof, as defined hereinbefore, for use in the treatment of cancer.

As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular cell-proliferation disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. A unit dose in the range, for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged.

The HDAC inhibitory activity defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. In the field of medical oncology it is normal practice to use a combination of different forms of treatment to treat each patient with cancer. In medical oncology the other component(s) of such conjoint treatment in addition to the cell cycle inhibitory treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents:

- (i) other cell cycle inhibitory agents that work by the same or different mechanisms from those defined hereinbefore, for example cyclin dependent kinase (CDK) inhibitors, in particular CDK2 inhibitors;
- (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene, idoxifene), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrozole, vorazole, exemestane), antiprogestogens, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone 5 $\alpha$ -dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function) and inhibitors of growth factor function, (such growth factors include for example vascular endothelial growth factor, epithelial growth factor, platelet derived growth factor and hepatocyte growth factor such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors);

(iii) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside); antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin, mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); antimitotic agents (for example vinca alkaloids like vincristine and taxoids like taxol, taxotere); topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan);

(iv) antiangiogenic agents that work by different mechanisms from those defined hereinbefore (for example receptor tyrosine kinases like Tie-2, inhibitors of integrin  $\alpha v \beta 3$  function, angiostatin, razoxin, thalidomide), and including vascular targeting agents; and

(v) differentiation agents (for example retinoic acid and vitamin D).

According to this aspect of the invention there is provided a pharmaceutical product comprising a compound of the formula (I) as defined hereinbefore and an additional anti-tumour substance as defined hereinbefore for the conjoint treatment of cancer.

In addition to their use in therapeutic medicine, the compounds of formula (I) and their pharmaceutically acceptable salts or *in vivo* hydrolysable esters or amides thereof, are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

For the benefit of the reader, where a pharmaceutical composition comprising a compound of formula (I), or the use of a compound of formula (I) as a medicament, or the use of a compound of formula (I) in a method of treatment, or the use of a compound of formula (I) in the manufacture of a medicament, or the use of a compound of formula (I) in the treatment of cancer, is described herein, it is to be understood that here, the definition of the compound of formula (I) includes the compounds N-(2-amino-6-hydroxyphenyl)-4-(1-methylhomopiperazin-4-yl)benzamide;

N-(2-amino-6-methylphenyl)-4-(1-methylhomopiperazin-4-yl)benzamide;

N-(2-aminophenyl)-4-(1-*t*-butoxycarbonylhomopiperazin-4-yl)benzamide; and N-(2-aminophenyl)-4-(1-methylhomopiperazin-4-yl)benzamide.

The invention will now be illustrated in the following Examples in which, generally :

- (i) operations were carried out at ambient temperature, *i.e.* in the range 17 to 25°C and under an atmosphere of an inert gas such as argon unless otherwise stated;
- (ii) evaporations were carried out by rotary evaporation *in vacuo* and work-up procedures were carried out after removal of residual solids by filtration;
- (iii) column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or Merck Lichroprep RP-18 (Art. 9303) reversed-phase silica obtained from E. Merck, Darmstadt, Germany or high pressure liquid chromatography (HPLC) was performed on C18 reverse phase silica, for example on a Dynamax C-18 60Å preparative reversed-phase column;
- (iv) yields, where present, are not necessarily the maximum attainable;
- (v) in general, the structures of the end-products of the Formula (I) were confirmed by nuclear magnetic resonance (NMR) and/or mass spectral techniques; fast-atom bombardment (FAB) mass spectral data were obtained using a Platform spectrometer and, where appropriate, either positive ion data or negative ion data were collected; NMR chemical shift values were measured on the delta scale [proton magnetic resonance spectra were determined using a Jeol JNM EX 400 spectrometer operating at a field strength of 400 MHz, Varian Gemini 2000 spectrometer operating at a field strength of 300MHz or a Bruker AM300 spectrometer operating at a field strength of 300MHz]; the following abbreviations have been used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad;
- (vi) intermediates were not generally fully characterised and purity was assessed by thin layer chromatographic, HPLC, infra-red (IR) and/or NMR analysis;
- (vii) melting points are uncorrected and were determined using a Mettler SP62 automatic melting point apparatus or an oil-bath apparatus; melting points for the end-products of the formula (I) were determined after crystallisation from a conventional organic solvent such as ethanol, methanol, acetone, ether or hexane, alone or in admixture;
- (viii) the following abbreviations have been used:-

DMF N,N-dimethylformamide

DMSO dimethylsulphoxide


THF tetrahydrofuran

**Example 1****N-(2-Aminophenyl)-4-pyridin-4-ylbenzamide**

N-(2-t-Butoxycarbonylaminophenyl)-4-pyridin-4-ylbenzamide (Method 1; 100 mg, 0.26 mmol), 1,4-dioxane (2 ml) and a 4M solution of hydrochloric acid in dioxane (2 ml) were stirred at ambient temperature for approximately 20 hours. The resultant precipitate was collected by filtration and washed with iso-hexane and diethyl ether and dried *in vacuo* to give the title compound as its hydrochloride (43 mg, 46%). NMR Spectrum: (DMSO- $d_6$ ) 7.31 (m, 2H), 7.39 (t, 1H), 7.54 (t, 1H), 8.17 (d, 2H), 8.30 (d, 2H), 8.40 (d, 2H), 8.96 (d, 2H), 10.62 (s, 1H); Mass Spectrum:  $M+H^+$  290.

**Example 2**

Using an analogous procedure to that described in Example 1, the appropriate N-(2-t-butoxycarbonylaminophenyl)-benzamide starting material was reacted to give the compounds described in Table 1. Unless otherwise stated, each compound was obtained as its hydrochloride salt.

**Table 1**

Note	R <sup>1</sup>	Analytical Data	SM
1	quinolin-8-yl	<u>NMR Spectrum</u> : (DMSO- $d_6$ ) 7.37 (t, 1H), 7.49 (t, 1H), 7.62 (d, 1H), 7.78 (m, 5H), 7.93 (d, 1H), 8.18 (d, 1H), 8.31 (d, 2H), 8.72 (d, 1H), 9.04 (dd, 1H), 10.75 (s, 1H); <u>Mass Spectrum</u> : $M+H^+$ 340.	Meth 2
2	pyridin-3-yl	<u>NMR Spectrum</u> : (DMSO- $d_6$ ) 7.32 (m, 2H), 7.43 (d, 1H), 7.57 (d, 1H), 7.95 (dd, 1H), 8.03 (d, 2H), 8.27 (d, 2H), 8.72 (d, 1H), 8.83 (d, 1H), 9.25 (s, 1H), 10.60 (s,	Meth 3

		1H); <u>Mass Spectrum</u> : $M+H^+$ 290.	
3	pyridin-2-yl Formic acid salt	<u>NMR Spectrum</u> : (DMSO- $d_6$ ): 6.63 (t, 1H), 6.80 (d, 1H), 6.98 (t, 1H), 7.23 (d, 1H), 7.44 (t, 1H), 7.95 (t, 1H), 8.13 (m, 3H), 8.22 (d, 2H), 8.72 (d, 1H), 9.74 (s, 1H); <u>Mass Spectrum</u> : $M+H^+$ 290.	Meth 4
4	6-(methoxy)-1,2-pyrazin-3-yl	<u>NMR Spectrum</u> : (DMSO- $d_6$ ) 4.09 (s, 3H), 7.32 (m, 4H), 7.49 (m, 1H), 8.24 (m, 5H), 10.46 (s, 1H); <u>Mass Spectrum</u> : $M+H^+$ 321.	Meth 5
5	furan-3-yl	<u>NMR Spectrum</u> : (DMSO- $d_6$ ) 7.09 (s, 1H), 7.25 (m, 3H), 7.58 (d, 1H), 7.83 (d, 3H), 8.06 (d, 2H), 8.33 (s, 1H), 10.32 (s, 1H); <u>Mass Spectrum</u> : $M+H^+$ 279.	Meth 6
6	2-methylpyridin-4-yl	<u>NMR Spectrum</u> : (DMSO- $d_6$ ) 2.82 (s, 3H), 7.21 (m, 1H), 7.29 (m, 2H), 7.51 (d, 2H), 8.20 (d, 2H), 8.31 (m, 3H), 8.41 (s, 1H), 8.89 (d, 1H), 10.51 (s, 1H); <u>Mass Spectrum</u> : $M+H^+$ 304.	Meth 7
7	2-fluoropyridin-4-yl	<u>NMR Spectrum</u> : (DMSO- $d_6$ ) 7.26-7.33 (m, 3H), 7.49 (d, 1H), 7.68 (s, 1H), 7.83 (m, 1H), 8.08 (d, 2H), 8.23 (d, 2H), 8.37 (d, 1H), 10.50 (s, 1H); <u>Mass Spectrum</u> : $M+H^+$ 308.	Meth 8
8	thiazol-2-yl	<u>NMR Spectrum</u> : (DMSO- $d_6$ ) 7.39 (t, 1H), 7.48 (t, 1H), 7.56 (d, 1H), 7.64 (d, 1H), 7.92 (d, 1H), 8.02 (d, 1H), 8.13 (d, 2H), 8.27 (d, 2H), 10.77 (s, 1H); <u>Mass Spectrum</u> : $M+H^+$ 296.	Meth 9
9	2-amino-pyrimidin-6-yl	<u>NMR Spectrum</u> : (DMSO- $d_6$ ) 7.32 (m, 2H), 7.41 (m, 1H), 7.57 (m, 2H), 8.30	Meth 10

		(m, 4H), 8.51 (d, 1H), 10.64 (s, 1H); <u>Mass Spectrum</u> : $M+H^+$ 306.	
10	pyrimidin-6-yl	<u>NMR Spectrum</u> : (DMSO- $d_6$ ) 7.33 (m, 3H), 7.52 (m, 1H), 8.25 (m, 3H), 8.40 (d, 2H), 8.95 (d, 1H), 9.33 (s, 1H), 10.52 (s, 1H); <u>Mass Spectrum</u> : $M+H^+$ 291.	Meth 11
11	2-chloro-pyrimidin-6-yl	<u>NMR Spectrum</u> : (DMSO- $d_6$ ) 7.39 (m, 2H), 7.46 (dd, 1H), 7.58 (dd, 1H), 8.30 (m, 3H), 8.39 (d, 2H), 8.93 (d, 1H), 10.72 (s, 1H); <u>Mass Spectrum</u> : $M+H^+$ 325.	Meth 12

**Example 3****N-(2-Aminophenyl)-4-morpholinobenzamide**

A solution of 1-(N-t-Butoxycarbonylamino)-2-aminobenzene (Method 17; 104 mg, 0.5 mmol) in DMF (1.6 ml) was added to 4-morpholino benzoic acid (149 mg, 0.5 mmol followed by 4-(4,6-dimethoxy-1,3,5-triazinyl-2-yl)-4-methylmorpholinium chloride (Method 18, 138 mg, 0.5 mmol) and the reaction mixture stirred at ambient temperature for 48 hours. The solvent was removed *in vacuo* and the resultant residue partitioned between ethyl acetate and water. The organic phase was separated, then washed with water, brine and dried over sodium sulfate then filtered. The organic extracts were concentrated by half and a 4M solution of hydrochloric acid in 1,4-dioxane (1 ml) added. The reaction mixture was stirred at ambient temperature for a further 64 hours and the resultant precipitate was collected by filtration. This solid was purified by preparative mass triggered HPLC, eluting with an increasing gradient of acetonitrile in water (which contains 5% (v/v) of a 1% (v/v) solution of formic acid in methanol) to afford the title compound (17 mg, 12%); NMR Spectrum: (DMSO- $d_6$ ) 3.25 (m, 4H), 3.76 (m, 4H), 4.83 (s, 2H), 6.60 (td, 1H), 6.79 (dd, 1H), 6.96 (td, 1H), 7.01 (d, 2H), 7.16 (dd, 1H), 7.90 (d, 2H), 9.31 (brs, 1H); Mass Spectrum:  $M+H^+$  298.



**Example 4****N-(2-Aminophenyl)-4-(1-methylpiperidin-4-yl)benzamide**

N-(2-Aminophenyl)-4-piperidin-4-ylbenzamide (Example 5, 48 mg, 0.163 mmol) was stirred and dissolved in anhydrous DMF (2 ml) at ambient temperature. Potassium carbonate (23 mg, 0.163 mmol) was added followed by iodomethane (0.01 ml, 0.163 mmol) and the mixture stirred for 3 hours. The reaction mixture was diluted with water (20 ml) and extracted with ethyl acetate. The combined extracts were washed once with brine, dried over magnesium sulfate, filtered and the solvent evaporated to give the title compound as a colourless solid (16 mg, 32%); NMR Spectrum: (DMSO- $d_6$ ) 1.70 (m, 4H), 1.96 (m, 2H), 2.18 (s, 3H), 2.85 (m, 2H), 3.03 (m, 1H), 4.84 (b, 2H), 6.57 (m, 1H), 6.76 (d, 1H), 6.95 (m, 1H), 7.16 (d, 1H), 7.36 (d, 2H), 7.99 (d, 2H), 9.54 (b, 1H); Mass Spectrum:  $M+H^+$  310.

**Example 5****N-(2-Aminophenyl)-4-piperidin-4-ylbenzamide**

A solution of 4M HCl/dioxane (5 ml, 20 mmol) was added to a stirred solution of N-(2-t-butoxycarbonylaminophenyl)-4-(1-t-butoxycarbonylpiperidin-4-yl)benzamide (Method 15, 693 mg, 1.40 mmol) in 1,4-dioxane (5 ml) and the mixture stirred at ambient temperature for 18 hours. The resultant precipitate was filtered and washed with diethyl ether. The resultant solid was dissolved in water and basified to pH 12 with 2N NaOH solution. The resultant precipitate was filtered, washed with water and dried under vacuum to give the title compound (338 mg, 82%); NMR Spectrum: (DMSO- $d_6$ ) 1.52 (m, 2H), 1.69 (m, 2H), 2.60 (m, 3H), 3.02 (m, 2H), 4.84 (br, 2H), 6.58 (m, 1H), 6.76 (d, 1H), 6.95 (m, 1H), 7.16 (d, 1H), 7.34 (d, 2H), 7.89 (d, 2H), 9.53 (br, 1H); Mass Spectrum:  $M+H^+$  296.

**Example 6****N-(2-Aminophenyl)-4-(1-methylpiperazin-4-yl)benzamide**

N-(2-t-Butoxycarbonylaminophenyl)-4-(1-methylpiperazin-4-yl)benzamide (Method 16; 196 mg, 0.48 mmol) was dissolved in HCl (1M in diethyl ether, 7.2 ml, 7.2 mmol) and stirred at ambient temperature for 24 hours. The resultant precipitate was collected by filtration and washed with diethyl ether. To the solid was added a 2M solution of aqueous sodium hydroxide solution (5 ml) and the solution extracted with ethyl acetate. The combined organic extracts were dried over magnesium sulfate, filtered and evaporated to afford the title compound as a colourless solid (16 mg, 11%); NMR Spectrum: ( $CDCl_3$ ) 2.36 (s, 3H), 2.57 (t,

4H), 3.33 (t, 4H), 3.88 (br, 2H), 6.81 (m, 2H), 6.91 (d, 2H) 7.06 (t, 1H), 7.27 (d, 1H), 7.79 (s, 1H), 7.80 (m, 2H); Mass Spectrum:  $M+H^+$  311.

### Example 7

#### 5 **N-(2-Aminophenyl)-4-[2-(3-morpholinoaminopropyl)-pyrimidin-6-yl]benzamide**

N-(2-Aminophenyl)-4-[2-(3-morpholinoaminoethyl)-pyrimidin-6-yl]benzamide trihydrochloride (Method 19, 28 mg, 0.052 mmol) was dissolved in water (2 ml) and basified to pH 10 by the addition of 28% aqueous ammonium hydroxide solution (2 drops). The resultant precipitate was collected by filtration and dried under vacuum at 40°C overnight to afford the title compound as a yellow solid (9 mg, 40%); NMR (DMSO- $d_6$ ): 1.75 (m, 2H), 2.37 (m, 6H), 3.41 (brm, 2H), 3.59 (m, 4H), 4.92 (s, 2H), 6.62 (t, 1H), 6.80 (d, 1H), 6.99 (t, 1H), 7.21 (m, 2H), 7.28 (t, 1H), 8.11 (d, 2H), 8.22 (d, 2H), 8.39 (d, 1H), 9.74 (s, 1H); Mass Spectrum:  $M+H^+$  433.

### 15 Example 8

#### **N-(2-Aminophenyl)-4-[2-(3-morpholinoaminoethyl)-pyrimidin-6-yl]benzamide**

N-(2-Aminophenyl)-4-[2-(3-morpholinoaminoethyl)-pyrimidin-6-yl]benzamide trihydrochloride (Method 24, 22 mg, 0.042 mmol) was reacted in an analogous manner to that described for Example 7 to afford the title compound as a pale yellow solid (12 mg, 68%); NMR (DMSO- $d_6$ ): 2.45 (m, 4H), 2.54 (m, 2H), 3.51 (m, 2H), 3.59 (m, 4H), 4.92 (s, 2H), 6.62 (t, 1H), 6.80 (d, 1H), 6.99 (t, 1H), 7.07 (t, 1H), 7.20 (d, 1H), 7.24 (d, 1H), 8.11 (d, 2H), 8.23 (d, 2H), 8.40 (d, 1H), 9.74 (s, 1H); Mass Spectrum:  $M+H^+$  419.

### Preparation of the Starting Materials

25 The starting materials for the above examples are either commercially available or are readily prepared by standard methods from known materials. For example the following reactions are illustrations but not limitations of the preparation of some of the starting materials used in the above reactions.

### 30 Method 1

#### **N-(2-t-Butoxycarbonylaminoethylphenyl)-4-pyridin-4-ylbenzamide**

N-(2-t-Butoxycarbonylaminoethylphenyl)-4-bromobenzamide (Method 14; 136 mg, 0.33 mmol), pyridine-4-boronic acid (48 mg, 0.39 mmol), *tetrakis*(triphenylphosphine) palladium

(5 mg, 0.005 mmol), THF (2 ml) and a saturated aqueous solution of sodium hydrogen carbonate

(2 ml) were stirred at 55°C under an atmosphere of argon for 96 hours. The cooled mixture was partitioned between ethyl acetate and water. The organics were washed with brine, dried over magnesium sulfate, filtered and evaporated, to give the title compound (103 mg, 80%), which was used without further purification; Mass Spectrum:  $M+H^+$  390.

### Method 2

#### **N-(2-t-Butoxycarbonylaminophenyl)-4-quinolin-8-ylbenzamide**

N-(2-t-Butoxycarbonylaminophenyl)-4-bromobenzamide (Method 14; 200 mg, 0.5 mmol), 8-quinoline boronic acid (104 mg, 0.6 mmol), *tetrakis*(triphenylphosphine)palladium (8 mg, 0.007 mmol), 1,2-dimethoxyethane (3 ml) and a saturated aqueous solution of sodium hydrogen carbonate (3 ml) were stirred at 80°C under an atmosphere of argon for 20 hours. The mixture was allowed to cool before being partitioned between ethyl acetate and water. The organics were washed with brine, dried over magnesium sulfate, filtered and evaporated. The resultant residue was purified by flash column chromatography, eluting with methanol/dichloromethane (0-10%), to give the title compound (201 mg, 84%); NMR Spectrum: (DMSO- $d_6$ ): 1.47 (s, 9H), 7.20 (m, 2H), 7.60 (m, 4H), 7.73 (t, 1H), 7.84 (t, 3H), 8.06 (d, 2H), 8.47 (d, 1H), 8.68 (s, 1H), 8.93 (m, 1H), 9.91 (s, 1H), Mass Spectrum:  $M+H^+$ : 440.

### Method 3

#### **N-(2-t-Butoxycarbonylaminophenyl)-4-pyridin-3-ylbenzamide**

The title compound was prepared using the procedure of Method 2 and used without further purification; Mass Spectrum:  $M+H^+$  390.

### Method 4

#### **N-(2-t-Butoxycarbonylaminophenyl)-4-pyridin-2-ylbenzamide**

N-(2-t-Butoxycarbonylaminophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Method 13; 132 mg, 0.3 mmol), 2-bromopyridine (40 mg, 0.25 mmol), *tetrakis*(triphenylphosphine)palladium (4 mg, 0.004 mmol), 1,2-dimethoxyethane (1.5 ml) and a saturated aqueous solution of sodium hydrogen carbonate (1.5 ml) were stirred at 80-85°C under an atmosphere of argon for 24 hours. The mixture was allowed to cool before

being partitioned between ethyl acetate and water. The organics were separated, washed with brine, dried over magnesium sulfate, filtered and evaporated to yield the title compound (86 mg, 74%) which was used in the next reaction without further purification; Mass Spectrum:  $M+H^+$  390.

5


**Method 5-12**

Using an analogous procedure to that described in Method 4, the

N-(2-t-butoxycarbonylamino-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)

benzamide starting material was reacted with the appropriate bromo compound to give the

10 compounds described in Table 2. Where required, the crude residues were purified by flash column chromatography, eluting with methanol/dichloromethane (1:10).

**Table 2**

Method	R <sup>1</sup>	Analytical Data	SM
5	6-(methoxy)-1,2-pyrazin-3-yl	<u>NMR Spectrum</u> : (DMSO-d <sub>6</sub> ) 1.44 (s, 9H), 4.09 (s, 3H), 7.14 (m, 2H), 7.34 (d, 1H), 7.57 (t, 2H), 8.09 (d, 2H), 8.22 (d, 2H), 8.26 (d, 1H); <u>Mass Spectrum</u> : $M+H^+$ 421.	Meth 13
6	furan-3-yl	<u>Mass Spectrum</u> : ( $M+H^+$ -tBu) 323.	Meth 13
7	2-methylpridin-4-yl	<u>NMR Spectrum</u> : (DMSO-d <sub>6</sub> ) 1.46 (s, 9H), 2.57 (s, 3H), 7.20 (m, 2H), 7.59 (m, 3H), 7.69 (s, 1H), 7.98 (d, 2H), 8.10 (d, 2H), 8.56 (d, 1H), 8.67 (s, 1H), 9.92 (s, 1H); <u>Mass Spectrum</u> : $M+H^+$ 404.	Meth 13

8	2-fluoropyridin-4-yl	<u>NMR Spectrum</u> : (DMSO-d <sub>6</sub> ) 1.46 (s, 9H), 7.20 (m, 2H), 7.57 (m, 2H), 7.65 (s, 1H), 7.81 (m, 1H), 8.06 (d, 2H), 8.12 (d, 2H), 8.37 (d, 1H), 8.68 (s, 1H), 9.94 (s, 1H); <u>Mass Spectrum</u> : (M+H <sup>+</sup> - Boc) 308.	Meth 13
9	1,3-thiazol-2-yl	<u>Mass Spectrum</u> : (M+H <sup>+</sup> - tBu) 340.	Meth 13
10	2-amino-1,3-pyrimidin-6-yl	<u>Mass Spectrum</u> : (M+Na <sup>+</sup> ) 428.	Meth 13
11	1,3-pyrimidin-6-yl	<u>Mass Spectrum</u> : (M+H <sup>+</sup> - tBu) 335.	Meth 13
12	2-chloro-1,3-pyrimidin-6-yl	<u>NMR Spectrum</u> : (DMSO-d <sub>6</sub> ) 1.46 (s, 9H), 7.23 (m, 2H), 7.57 (t, 2H), 8.15 (d, 2H), 8.29 (d, 1H), 8.38 (d, 2H), 8.73 (br, 1H), 8.91 (d, 1H), 10.00 (s, 1H); <u>Mass Spectrum</u> : (M+H <sup>+</sup> - tBu) 369.	Meth 13

**Method 13**

**N-(2-t-Butoxycarbonylamino-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzamide**

- 5 N-(2-t-Butoxycarbonylamino-phenyl)-4-bromobenzamide (Method 14; 3.0 g, 7.7 mmol) was added to a solution of bis-pinacolato diboron (2.3g, 9.2 mmol), 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium (II) chloride (157 mg, 0.19 mmol) and potassium acetate (2.3 g, 23 mmol) in DMF (48 ml) at 80°C under an atmosphere of argon for 20 hours. The mixture was allowed to cool and the solvent removed *in vacuo*. The
- 10 residue was partitioned between ethyl acetate and water. The organics were washed with brine, dried over magnesium sulphate and evaporated to give the title compound (3.9 g, quantitative), which was used without further purification; NMR Spectrum: (DMSO-d<sub>6</sub>) 1.14 (s, 6H), 1.31 (s, 9H), 1.43 (s, 6H), 7.16 (m, 2H), 7.52 (m, 2H), 7.79 (d, 2H), 7.95 (d, 2H), 8.66 (s, 1H), 9.86 (s, 1H); Mass Spectrum: (M+H<sup>+</sup>-Boc) 383.

**Method 14****N-(2-t-Butoxycarbonylamino-phenyl)-4-bromobenzamide**

4-(4,6-Dimethoxy-1,3,5-triazinyl-2-yl)-4-methylmorpholinium chloride (Method 18; 5.4 g, 19.4 mmol) was added to a solution of 4-bromobenzoic acid (3.5 g, 17.4 mmol) and 1-(N-t-butoxycarbonylamino)-2-aminobenzene (Method 17; 4.3 g, 20.9 mmol) in DMF (100 ml) and stirred at ambient temperature for 20 hours. The reaction mixture was partitioned between water and ethyl acetate. The organics were washed with a saturated aqueous solution of sodium hydrogen carbonate, water, 1M aqueous hydrochloric acid, water and brine, before being dried over magnesium sulfate. The organics were then evaporated to give the title compound (7.1 g, quantitative), which was used without further purification. NMR Spectrum: (DMSO-d<sub>6</sub>): 1.45 (s, 9H), 7.18 (m, 2H), 7.54 (m, 2H), 7.76 (d, 2H), 7.90 (d, 2H), 8.63 (s, 1H), 9.86 (s, 1H); Mass Spectrum: (M+H<sup>+</sup> - Boc) 291.

**Method 15****N-(2-t-Butoxycarbonylamino-phenyl)-4-(1-t-butoxycarbonylpiperidin-4-yl)benzamide**

1-(N-t-Butoxycarbonylamino)-2-aminobenzene (Method 17, 3.1 g, 14.7 mmol) was added to a stirred solution of 4-(1-t-butoxycarbonylpiperidin-4-yl)benzoic acid (4.1 g, 13.4 mmol) in DMF (50 ml) and the mixture stirred at ambient temperature for 10 minutes. 4-(4,6-dimethoxy-1,3,5-triazinyl-2-yl)-4-methylmorpholinium chloride (Method 18, 4.45 g, 16.1 mmol) was added and the mixture stirred at ambient temperature for 24 hours. The solvent was evaporated and the residue was dissolved in ethyl acetate (100 ml) and washed with water. The organics were dried over magnesium sulfate, filtered and evaporated. The resultant gum was purified by flash chromatography using 1% methanol/dichloromethane to give the title compound as a foam (5.44 g, 82%); NMR Spectrum: (DMSO-d<sub>6</sub>) 1.41 (s, 9H), 1.43 (s, 9H), 1.54 (m, 2H), 1.77 (m, 2H), 2.79 (m, 3H), 4.08 (m, 2H), 7.15 (m, 2H), 7.40 (d, 2H), 7.52 (m, 2H), 7.87 (d, 2H), 8.60 (br, 1H), 9.74 (br, 1H), Mass Spectrum: (M+H<sup>+</sup>-Boc) 396.

**Method 16****N-(2-t-Butoxycarbonylamino-phenyl)-4-(1-methylpiperazin-4-yl)benzamide**

4-(1-Methylpiperazin-4-yl)benzoic acid (250 mg, 1.13 mmol) and 1-(N-t-butoxycarbonylamino)-2-aminobenzene (Method 17, 331 mg, 1.59 mmol) were dissolved in DMF (3 ml). 4-(4,6-dimethoxy-1,3,5-triazinyl-2-yl)-4-methylmorpholinium chloride (Method 18, 313 mg, 1.13 mmol) was added and the resulting solution was stirred for 20 hours at

ambient temperature. The solution was poured into water and extracted several times with ethyl acetate. The combined organic extracts were dried over magnesium sulfate and evaporated. The residue was purified by flash chromatography (eluting with 99:1 → 9:1 dichloromethane:methanol) to afford the title compound as a colourless gum which  
5 crystallised on trituration (240 mg, 52%); Mass Spectrum:  $M+H^+$  411.

### Method 17

#### **1-(N-t-Butoxycarbonylamino)-2-aminobenzene**

The title compound was prepared according to the literature method described in Seto,

10 C, T.; Mathias, J. P.; Whitesides, G. M.; *J. Am. Chem. Soc.*, **1993**, *115*, 1321-1329.

### Method 18

#### **4-(4,6-Dimethoxy-1,3,5-triazinyl-2-yl)-4-methylmorpholinium chloride**

4-(4,6-Dimethoxy-1,3,5-triazinyl-2-yl)-4-methylmorpholinium chloride was prepared  
15 according to the literature procedure described in Kunishima, M., Kawachi, C., Morita, J., Terao, K., Iwasaki, F., Tani, S., *Tetrahedron*, **1999**, *55*, 13159-13170.

### Method 19

#### **N-(2-Aminophenyl)-4-[2-(3-morpholinoaminopropyl)-pyrimidin-6-yl]benzamide 20 trihydrochloride**

N-(2-t-Butoxyaminophenyl)-4-[2-(3-morpholinoaminopropyl)-pyrimidin-6-yl]benzamide (Method 20, 64 mg, 0.120 mmol) was suspended in 1,4 dioxane (1.5 ml) and a 4M solution of hydrogen chloride in 1,4-dioxane (1 ml) added. The reaction mixture was stirred at ambient temperature for 64 hours. The reaction mixture was diluted with diethyl  
25 ether, and the resultant precipitate was collected by filtration, washed with diethyl ether and air dried, to yield the title compound (as its hydrochloride salt) as an off white solid (62 mg, 95%); Mass Spectrum:  $M+H^+$  433.

### Method 20

#### **N-(2-t-Butoxyaminophenyl)-4-[2-(3-morpholinoaminopropyl)-pyrimidin-6-yl]benzamide 30**

N-(2-t-Butoxyaminophenyl)-4-(2-methylsulfonyl-pyrimidin-6-yl)benzamide (Method 21, 62.5 mg, 0.133 mmol) was dissolved in a mixture of THF (2 ml) and *N,N*-

dimethylacetamide (2 ml) and *N*-(3-aminopropyl)morpholine (60  $\mu$ l, 0.411 mmol) added. The reaction mixture was heated to 50°C and stirred for 2 hours. The reaction mixture was then cooled and solvents removed under reduced pressure. The resultant oil was purified by elution through silica with a 5% methanol in dichloromethane, to yield the title compound as a colourless solid (65 mg, 92%); NMR Spectrum: (DMSO- $d_6$ ) 1.45 (s, 9H), 1.74 (m, 2H), 2.37 (m, 6H), 3.40 (br, 2H), 3.59 (m, 4H), 7.20 (m, 2H), 7.23 (d, 1H), 7.34 (t, 1H), 7.57 (d, 1H), 8.08 (d, 2H), 8.26 (d, 2H), 8.40 (m, 1H), 8.72 (s, 1H), 9.94 (s, 1H); Mass Spectrum:  $M+H^+$  534.

#### 10 Method 21

##### **N-(2-*t*-Butoxyaminophenyl)-4-(2-methylsulfonyl-pyrimidin-6-yl)benzamide**

*N*-(2-*t*-Butoxyaminophenyl)-4-(2-thiomethyl-pyrimidin-6-yl)benzamide (Method 22, 140 mg, 0.32 mmol) was dissolved in methanol (8 ml) and a small amount of ethyl acetate, followed by a solution of Oxone<sup>®</sup> (630 mg, 1.02 mmol) in water (4 ml). The resultant suspension was stirred at ambient temperature for 1 hour before being partitioned between ethyl acetate and a mixture of water and saturated sodium bicarbonate. The organic phase was separated and the aqueous phase extracted with further aliquots of ethyl acetate. The combined organic extracts were washed with brine and dried over magnesium sulfate. Evaporation to dryness afforded the title compound as an off white powder (126 mg, 84%); NMR Spectrum: (DMSO- $d_6$ ) 1.45 (s, 9H), 3.54 (s, 3H), 7.20 (m, 2H), 7.57 (t, 2H), 8.18 (d, 2H), 8.48 (d, 2H), 8.54 (s, 1H), 8.73 (s, 1H), 9.20 (d, 1H), 10.02 (s, 1H); Mass Spectrum: ( $M+H^+$  -Boc) 369.

#### Method 22

##### 25 **N-(2-*t*-Butoxyaminophenyl)-4-(2-thiomethyl-pyrimidin-6-yl)benzamide**

4-Iodo-2-methylthiopyrimidine (Method 23, 360 mg, 1.43 mmol) was reacted with *N*-(2-*t*-butoxycarbonylaminophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzamide (Method 13, 631 mg, 1.44 mmol) in an analogous manner to that described in Method 4 to yield the crude title compound. This was purified by elution through silica with a solution of ethyl acetate in isohexane (25% to 50% (v/v)) to afford the pure title compound as a pale yellow foam (306 mg, 49%); NMR Spectrum: (DMSO- $d_6$ ) 1.45 (s, 9H), 2.63 (s, 3H), 7.20 (m,



2H), 7.57 (t, 2H), 7.91 (d, 1H), 8.13 (d, 2H), 8.37 (d, 2H), 8.72 (s, 1H), 8.77 (d, 1H), 9.97 (s, 1H); Mass Spectrum: (M+H<sup>+</sup> - tBu) 381.

### Method 23

#### 5 **4-Iodo-2-methylthiopyrimidine**

4-Chloro-2-methylthiopyrimidine (5 g, 31.15 mmol) was added dropwise to a cooled 57% aqueous hydriodic acid solution (0°C). Stirring was continued at 0°C for 30 minutes, before warming to ambient temperature and stirring for 24 hours. Aqueous sodium bicarbonate was then carefully added and the resultant suspension basified to pH 9 by addition  
10 of sodium carbonate. The mixture was extracted with ethyl acetate and the extracts dried over magnesium sulfate and concentrated by reduced pressure. The resultant solid was dissolved in boiling isohexane and cooled by refrigeration overnight. The resultant solid was filtered and dried to afford the title compound as colourless needles (5.4 g, 69%); NMR Spectrum: (CDCl<sub>3</sub>) 2.55 (s, 3H), 7.40 (d, 1H), 7.98 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 253.

15

### Method 24

#### **N-(2-Aminophenyl)-4-[2-(3-morpholinoaminoethyl)-pyrimidin-6-yl]benzamide trihydrochloride**

N-(2-t-Butoxyaminophenyl)-4-[2-(3-morpholinoaminoethyl)-pyrimidin-6-yl]benzamide (Method 25, 59 mg, 0.113 mmol) was reacted in an analogous manner to that described for Method 19 to yield the title compound (as its hydrochloride salt) as a beige solid  
20 (56 mg, 94%); Mass Spectrum: M+H<sup>+</sup> 419.


### Method 25

#### 25 **N-(2-t-Butoxyaminophenyl)-4-[2-(3-morpholinoaminoethyl)-pyrimidin-6-yl]benzamide**

N-(2-t-Butoxyaminophenyl)-4-(2-methylsulfonyl-pyrimidin-6-yl)benzamide (Method 21, 62.5 mg, 0.133 mmol) was reacted with N-(2-aminoethyl)morpholine (60 µl, 0.457 mmol) in an analogous manner to that described in method 20 to yield the title compound as a pale yellow solid (66 mg, 96%); NMR Spectrum: (DMSO-d<sub>6</sub>) 1.46 (s, 9H), 2.45 (brm, 4H), 3.30 (m, 2H), 3.50 (brm, 2H), 3.58 (m, 4H), 7.14 (t, 1H), 7.17 (td, 1H), 7.22 (td, 1H), 7.25 (d, 1H),  
30 7.57 (d, 2H), 8.09 (d, 2H), 8.27 (d, 2H), 8.42 (d, 1H), 8.73 (s, 1H), 9.94 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 519.

Claims

1. A compound of the formula (I):



wherein:

**Ring A** is a heterocyclyl;

**R<sup>1</sup>** is halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>alkoxy,

- 10 C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkanoyloxy, *N*-(C<sub>1-6</sub>alkyl)amino, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, C<sub>1-6</sub>alkanoylamino, *N*-(C<sub>1-6</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>1-6</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-6</sub>alkoxycarbonyl, *N*-(C<sub>1-6</sub>alkyl)sulphamoyl, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>sulphamoyl or a group (B-E-); wherein,

**B** is selected from C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>3-8</sub>cycloalkyl,

- 15 C<sub>3-8</sub>cycloalkylC<sub>1-6</sub>alkyl, phenyl, heterocyclyl, phenylC<sub>1-6</sub>alkyl or heterocyclylC<sub>1-6</sub>alkyl;

wherein B may be optionally substituted on carbon by one or more D; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from G;

**E** is -N(R<sup>a</sup>)-, -O-, -C(O)O-, -OC(O)-, -C(O)-, -N(R<sup>a</sup>)C(O)-, -C(O)N(R<sup>a</sup>)-, -S(O)<sub>r</sub>-,

- 20 -SO<sub>2</sub>N(R<sup>a</sup>)-, -N(R<sup>a</sup>)SO<sub>2</sub>-; wherein R<sup>a</sup> is hydrogen or C<sub>1-6</sub>alkyl optionally substituted by one or more D and r is 0-2;

**D** is independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkanoyloxy, *N*-(C<sub>1-6</sub>alkyl)amino,

- 25 *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, C<sub>1-6</sub>alkanoylamino, *N*-(C<sub>1-6</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>1-6</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-6</sub>alkoxycarbonyl, *N*-(C<sub>1-6</sub>alkyl)sulphamoyl and *N,N*-(C<sub>1-6</sub>alkyl)<sub>2</sub>sulphamoyl;

G is selected from C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkylsulphonyl, C<sub>1-4</sub>alkoxycarbonyl, carbamoyl, N-(C<sub>1-4</sub>alkyl)carbamoyl, N,N-(C<sub>1-4</sub>alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

m is 0, 1, 2, 3 or 4; wherein the values of R<sup>1</sup> may be the same or different;

5 R<sup>2</sup> is halo;

n is 0, 1 or 2; wherein the values of R<sup>2</sup> may be the same or different;

R<sup>3</sup> is amino or hydroxy;

R<sup>4</sup> is halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C<sub>1-3</sub>alkyl, C<sub>2-3</sub>alkenyl, C<sub>2-3</sub>alkynyl, C<sub>1-3</sub>alkoxy,

10 C<sub>1-3</sub>alkanoyl, C<sub>1-3</sub>alkanoyloxy, N-(C<sub>1-3</sub>alkyl)amino, N,N-(C<sub>1-3</sub>alkyl)<sub>2</sub>amino,

C<sub>1-3</sub>alkanoylamino, N-(C<sub>1-3</sub>alkyl)carbamoyl, N,N-(C<sub>1-3</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>1-3</sub>alkylS(O)<sub>a</sub>

wherein a is 0 to 2, C<sub>1-3</sub>alkoxycarbonyl, N-(C<sub>1-3</sub>alkyl)sulphamoyl, N,N-(C<sub>1-3</sub>alkyl)<sub>2</sub>sulphamoyl;

p is 0, 1 or 2; wherein the values of R<sup>4</sup> may be the same or different;

or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester or amide thereof.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**